Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.
from The Medical News http://ift.tt/1FIbbmd
from The Medical News http://ift.tt/1FIbbmd
No comments:
Post a Comment